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Abstract: Discoidin domain receptor 2 (DDR2) is an atypical recep-
tor tyrosine kinase that binds to and is activated by collagen in the 
extracellular matrix. Recent exon sequencing studies have identi-
fied DDR2 to be mutated with a 3% to 4% incidence in squamous 
cell cancers of the lung. This article summarizes the current state of 
knowledge of DDR2 biology and signaling in lung squamous cell 
cancer. It also explores the context-dependent role of this receptor as 
both an oncogene and a tumor suppressor in cancer cells. Promising 
therapeutic opportunities based on existing and novel targeted small 
molecule inhibitors against DDR2 may provide new strategies for 
treating lung squamous cell cancer patients.
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Squamous cell cancers (SCCs) of the lung develop from bronchial epithelial cells as a result of squamous metaplasia 
and are typically found in smokers.1 The standard of care for 
this disease is a chemotherapy regimen of four to six cycles 
of platinum doublets in the first-line setting.2 Prognosis is 
often poor with objective response rates of 30% to 40% and 
a median survival of 12 months for patients with stage IIIb/
IV disease.3 Clinical trials of targeted therapies in lung SCCs 
have not shown any patient benefit and in some cases led to 
greater toxicity. For instance, treatment with the vascular endo-
thelial growth factor receptor inhibitor bevacizumab resulted in 
an increased risk of bleeding complications in SCC patients in 
phase II trials and is currently approved only in  non-squamous 
non–small-cell lung carcinoma.4,5 Another example is the insu-
lin-like growth factor-1 receptor inhibitor figitumumab that 
showed increased toxicity when combined with chemotherapy 
compared with chemotherapy alone, resulting in the closure of 
phase III clinical trials.6 The failure of these trials underscore 
the need for a comprehensive understanding of the biology of 
lung SCC, in particular how genetic aberrations manifest at the 
signaling level to promote tumorigenesis and dictate therapeu-
tic response. The differential responses to targeted therapies 
between lung adenocarcinomas and SCCs in the clinical setting 
suggest that the biology and genetic landscape of these two dis-
eases are unique. Indeed, recent lung SCC sequencing studies 
by Hammerman et al.7,8 demonstrate that the genomic aberra-
tions in SCCs are distinct from adenocarcinomas.
DDR2 AND LUNG SCCS
In an exon sequencing study, Hammerman et al.8 iden-
tified the discoidin domain receptor 2 (DDR2) gene as a 
potential oncogenic target in lung SCC. The authors screened 
290 tumors and cell lines and reported a 3.8% incidence of 
DDR2 point mutations in lung SCC samples. This frequency 
is similar to the incidence of EML4-ALK in lung adenocarci-
nomas.9 Additional DDR2 mutations at 4.4% frequency have 
since been identified in an independent cohort of lung SCC 
patients.10 It is likely that early targeted sequencing studies 
failed to identify any aberrations in the DDR2 gene because 
of small patient cohort size.11,12 A lower mutation frequency of 
1.1% was reported in a large-scale next generation sequencing 
study in a cohort of 178 SCC patients performed by the TCGA 
Network,13 whereas no mutations were found in a screen of 
166 SCC biopsies from Japanese patients.14 In the latter case, 
Sasaki et al14 proposed that their inability to detect any DDR2 
mutations may have been related to ethnic differences in the 
sample populations.
The DDR2 point mutations are not localized to hotspot 
regions and are distributed throughout the gene, including the 
extracellular ligand-binding discoidin domain and the cyto-
plasmic kinase domain. Interestingly, data emerging from 
lung adenocarcinoma sequencing studies have also identified 
DDR2 mutations at 2% to 5% frequency (http://www.cbio-
portal.org/).15 Again, these mutations are spread across the 
gene but were not found to be significantly enriched over the 
background mutational rate of the tumors analyzed. The bio-
logical role of DDR2 in lung adenocarcinoma remains to be 
investigated. DDR2 is a receptor tyrosine kinase, which also 
functions as an adhesion receptor that is activated by collagen, 
a major component of the extracellular matrix in the lung.16 
Hammerman et al.8 showed that a subset of these DDR2 
mutants is tumor promoting in cell lines in vitro. Depletion 
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of mutant DDR2 using RNA interference in lung SCC cells 
demonstrated oncogene addiction. Importantly, this class of 
mutations is sensitive to inhibition by the FDA-approved tyro-
sine kinase inhibitor dasatinib in both in vitro assays and in 
subcutaneous xenograft models in vivo, making it clinically 
actionable and amenable to rapid advancement into lung SCC 
trials.8,17
There have been two reports of tumor shrinkage in 
response to dasatinib treatment in lung SCC patients har-
boring the DDR2 kinase domain S768R mutation.8,18 In the 
first case described by Hammerman et al.8 a combination of 
erlotinib (an epithelial growth factor receptor inhibitor) and 
dasatinib was administered to a patient whose disease had 
progressed despite carboplatin and paclitaxel therapy. Within 
2 months of treatment, this patient showed a partial response 
and tumor shrinkage. She remained on the combination regi-
men for 14 months before discontinuation because of toxic-
ity. In the second case study reported by Pitini et al.,18 the 
patient had a rare instance of a BCR-ABL positive chronic 
myelogenous leukemia and a DDR2 S768R mutation in a 
lung SCC lesion. Dasatinib therapy resolved both the chronic 
myelogenous leukemia and the lung tumor after 10 weeks and 
the patient remained clinically well 8 months into the treat-
ment. These case studies provide an indication that a subset 
of DDR2 mutations is oncogenic in this disease. Ongoing 
phase II trials assessing the efficacy of dasatinib in lung SCC 
(NCT01491633 and NCT01514864) are undertaking corre-
lation analysis of DDR2 mutational status with response to 
therapy to validate the clinical relevance of these experimental 
findings.19
DDR2 SIGNALING NETWORKS
DDR2 has been implicated in a number of cancer types 
and has been shown to play a role in driving proliferation and 
metastasis (see Borza and Pozzi 20 and Valiathan et al.21 for 
recent excellent reviews on this topic). There is limited infor-
mation available on the signaling pathways activated by DDR2 
on collagen engagement. Work done by several research 
groups have shown that DDR2 activates important signaling 
components including SHC, SRC, JAK, ERK1/2, and PI3K 
(summarized in Fig. 1).16 In addition, Hammerman et al.8 used 
phosphorylation of STAT5 as a biological readout for DDR2 
activity, although this signaling protein is unlikely to be a bona 
fide downstream substrate of the DDR2 pathway but rather the 
result of a survival signaling cascade in the IL-3 dependent 
Ba/F3 murine cell line. DDR2 also exhibits crosstalk with 
other cell surface receptors such as the integrins and RTKs 
resulting in diversification of downstream signal transduction 
networks.22–25 Our laboratory has recently performed a global 
phosphoproteomic screen of DDR2 signaling activated by col-
lagen I and identified 45 signaling effectors downstream of 
this receptor.26 In addition to the previously identified signal-
ing nodes ERK1 and PI3K, these effectors also include novel 
protein substrates such as Lyn, SHP-2, SHIP-2, and PLCL2 
(Fig. 1). We further show that these signaling events are inde-
pendent of integrin activation by collagen and are specific to 
the DDR2 pathway. Similar to previous reports of signal trans-
duction pathway adaptation in the epithelial growth factor 
receptor mutants often found in lung adenocarcinoma,27,28 the 
identification of DDR2-specific signaling nodes will facilitate 
future studies on network reprogramming events that occur on 
acquisition of DDR2 mutations in cancer cells.
IS DDR2 AN ONCOGENE OR A TUMOR 
SUPPRESSOR?
There is some controversy regarding the role of DDR2 
in cancer. Although Hammerman et al.8 showed that a subset 
of the DDR2 mutants, including the extracellular discoidin 
domain variant L63V and kinase domain variant I638F, are 
oncogenic, these assays were performed in the absence of its 
physiological ligand collagen. Furthermore, the activation and 
phosphorylation status of the receptor in these mutants were 
not established in this study. Fibrillar collagen inhibits cancer 
cell growth and one mechanism by which this process occurs 
is through a DDR2-dependent cell cycle arrest in melanoma 
and fibrosarcoma cells.29–31 It is plausible that DDR2 functions 
in a context-dependent manner and in the presence of its natu-
ral ligand collagen may act as a tumor suppressor rather than 
an oncogene. In support of this notion, mRNA levels of DDR2 
are diminished in lung cancer tumors compared with matched 
normal lung tissue, suggesting a potential tumor suppressor 
role.11,14 This context dependence is reminiscent of the β1 
integrin adhesion receptor that promotes tumor formation in 
transgenic mouse models of breast cancer but exhibits tumor 
FIGURE 1.  Depiction of signaling pathways activated 
downstream of Discoidin domain receptor 2 (DDR2). Binding 
of collagen to the extracellular domain of DDR2 triggers the 
autophosphorylation of its cytoplasmic domain. This results 
in the recruitment of downstream adaptor proteins, kinases, 
and phosphatases including SHC, NCK1, SRC, and SHP-2. As 
a consequence, a series of canonical signaling pathways are 
initiated including the ERK1/2 and PI3K cascades.
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suppressor-like properties in the TRAMP prostate adenocar-
cinoma model.32,33
Intriguingly, our laboratory has shown that the I638F 
kinase domain mutant, unlike the L63V and G505 mutants, 
is incapable of receptor autophosphorylation and activation 
of its downstream effector SHP-2 when exposed to collagen 
stimulation.26 These data indicate that I638F is a loss of func-
tion mutation that eliminates receptor activation and effec-
tor signaling. Consistent with this idea, this kinase domain 
mutant was able to abrogate the growth suppressive properties 
of wildtype DDR2 in HEK293 cells grown in 3D collagen 
gels.26 It is not clear as to the mechanisms by which recep-
tor depletion (by RNA interference) or kinase inhibitor treat-
ment promotes cytotoxicity in lung SCC cell lines bearing the 
I638F kinase inactive DDR2 mutant.8 One potential explana-
tion is that DDR2 may possess additional kinase-independent 
oncogenic functions that are important for fuelling lung 
cancer cell growth. Alternatively, in the absence of intrinsic 
autophosphorylation capacity, DDR2 may be susceptible to 
transphosphorylation and activation by other tyrosine kinases 
such as SRC or insulin-like growth factor-1R.8,22,34 It should 
be noted that collagen accumulates in the lung during tumor 
progression, which may impact the biological properties of 
DDR2.35,36 In this respect, transgenic mouse models of mutant 
DDR2-driven lung SCC will undoubtedly shed light on the 
role of this receptor in the context of the in vivo lung tumor 
microenvironment.37
In addition to a direct role in regulating tumor cell 
growth, conflicting literature also exists for the role of DDR2 
in supporting metastatic growth. In particular, two groups 
have examined the function of DDR2 in the host stromal 
compartment as a regulator of cancer metastasis. In one 
study, Zhang et al.38 found that DDR2 expression is enriched 
in  tumor-associated endothelial cells in both colon carci-
noma and melanoma. Using a transgenic mouse model that 
is deficient for DDR2 as the host in an experimental system 
for metastatic melanoma, the authors showed that pulmonary 
metastasis was significantly reduced in the mutant mice ver-
sus control. This was attributed to a decrease in angiogenesis 
as a result of downregulation of proangiogenic genes such 
as VEGFR2 and upregulation antiangiogenic components 
including Ang-1. In contrast, Badiola et al.39 demonstrated the 
opposite effect in hepatic metastases of colon carcinoma. In 
their model, downregulation of DDR2 in the host mice gen-
erated a prometastatic niche in the liver leading to increased 
vascular endothelial growth factor and transforming growth 
factor-β expression and metastases. Collectively, these stud-
ies emphasize the complex nature of DDR2 interactions in 
both tumor and stromal cells and highlights the potential chal-
lenges associated with targeting this receptor.
DDR2 TARGETED THERAPY
There are several candidate small molecule inhibitors 
that selectively target DDR2. As discussed above, the multiki-
nase inhibitors dasatinib, imatinib, and nilotinib block DDR2 
kinase activity in an adenosine triphosphate (ATP)-competitive 
manner with varying levels of potency.17 Hammerman et al.8 
showed that a panel of lung SCC DDR2 mutants is selectively 
sensitive to these inhibitors. A recent report by the same group 
showed that prolonged exposure of dasatinib to lung cancer 
cell lines that were dasatinib sensitive and DDR2 dependent 
resulted in acquired drug resistance in vitro.40 Interestingly, 
using massively parallel sequencing, the authors identified two 
distinct mechanisms of dasatinib resistance. One mechanism 
is the acquisition of the gatekeeper T654I mutation on DDR2 
that increases the affinity for ATP and prevents drug binding.41 
The second is loss of NF1 expression through a splice site 
mutation. NF1 is a negative regulator of Ras and the authors 
showed that loss of this protein results in the maintenance of 
ERK1/2 survival signals even when DDR2 is inhibited by 
dasatinib, conferring drug resistance. This data suggest that to 
overcome potential drug resistance that may arise in lung SCC 
dasatinib trials, a combination regimen including an ERK1/2 
pathway inhibitor may be necessary.
The identification of a gatekeeper mutation also sug-
gests that alternative DDR2 inhibitors may be required to 
overcome acquired resistance. Additional DDR2 inhibitors 
that have been isolated include the recently identified alkaloid 
natural products discoipyrroles A-D and the chemotherapeutic 
Actinomycin D, although the mechanism of action of these 
compounds is less well characterized and it is not clear if the 
T654I mutant would be susceptible to inhibition.42–44 The Gray 
group has recently developed selective inhibitors against both 
DDR1 and DDR2 based on a scaffold for type II kinase inhibi-
tors primarily for use as chemical biology tools for functional 
studies.45 These tools will be invaluable in the dissection of 
mutant DDR2 function in lung SCC progression. Furthermore, 
these compounds provide the foundation for second genera-
tion DDR2 selective inhibitors that have the potential to mini-
mize toxicities seen in multitarget tyrosine kinase inhibitors 
such as dasatinib. A recent report of a phase II dasatinib trial 
in lung SCC patients was discontinued because of excess tox-
icity, including the development of grade 2 pleural effusions.46 
In addition to DDR2, dasatinib is a broadly specific tyrosine 
kinase inhibitor that targets BCR-ABL, SRC, PDGFR, c-KIT, 
and DDR1 among others.47,48 These additional targets may be 
responsible for the excess adverse effects observed in patients 
which may be overcome by more selective DDR2 inhibi-
tors. In addition to targeted inhibitors, a chemical proteomic 
screen has also identified DDR2 as a client protein of the 
HSP90 chaperone and is susceptible to protein degradation 
by HSP90 inhibitors.49 The potency of this class of inhibitors 
to specific DDR2 mutants has yet to be established but previ-
ous work on epithelial growth factor receptor mutants, and 
the  EML4-ALK translocation in lung adenocarcinoma would 
suggest that HSP90 inhibitors may preferentially degrade 
DDR2 mutants and could have utility as a potential therapeu-
tic in lung SCC.50,51
CONCLUSION
The studies described above highlight the promise of 
DDR2 as a potential new target in the treatment of lung SCC. 
Progress has been constrained by our limited knowledge of 
the biology of the DDR2 receptor and its oncogenic/tumor 
suppressive properties in lung SCC progression. It is clear 
that more research is required to delineate the signaling 
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pathways of DDR2 and how these events are modulated in 
the lung SCC mutants. In light of the failed trials with tar-
geted therapies in SCC, a more comprehensive understand-
ing of the biology of DDR2 and its mutants will be crucial 
in avoiding similar disappointing outcomes in ongoing and 
future dasatinib trials.
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